Literature DB >> 17317826

Circulating tumor cells as prognostic factor for distant metastases and survival in patients with primary uveal melanoma.

Ronny Schuster1, Nikolaos E Bechrakis, Andrea Stroux, Antonia Busse, Alexander Schmittel, Carmen Scheibenbogen, Eckhard Thiel, Michael H Foerster, Ulrich Keilholz.   

Abstract

PURPOSE: The aim of this study was to determine in patients with high-risk primary uveal melanoma whether the detection of circulating tumor cells by quantitative reverse transcription-PCR (RT-PCR) is of prognostic relevance. EXPERIMENTAL
DESIGN: Blood samples from 110 patients with high-risk nonmetastatic uveal melanoma were collected on the occasion of primary treatment or follow-up visit. mRNA expression of tyrosinase and MelanA/MART1 were analyzed by real-time RT-PCR and compared with clinical data at presentation and follow-up by univariate and multivariate analyses.
RESULTS: The RT-PCR assay yielded a positive result in 11 of 110 patients, with five positive findings for tyrosinase and five for MelanA/MART1, and one sample positive for both markers. At a median follow-up of 22 months, 25% of patients had developed metastases and 15% had died. Univariate statistical analysis revealed RT-PCR and the largest tumor diameter as important prognostic factors for the development of metastases and for survival. In a Cox proportional hazard model, RT-PCR result and largest tumor diameter predicted metastases (hazard ratios 7.3 and 2.6, respectively), whereas PCR result, largest tumor diameter, and Karnofsky performance status were significant variables for disease-specific survival (hazard ratios 22.6, 4.7, and 6.0, respectively). Analysis of individual RT-PCR results revealed both tyrosinase and MelanA/MART1 transcripts as independent prognostic factors.
CONCLUSION: The presence of tyrosinase or MelanA/MART1 transcripts is an independent prognostic factor in patients with high-risk primary uveal melanoma for subsequent development of metastases and for survival and can be used to select patients for adjuvant treatment studies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17317826     DOI: 10.1158/1078-0432.CCR-06-2329

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  20 in total

1.  Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma.

Authors:  Jo Eyles; Anne-Laure Puaux; Xiaojie Wang; Benjamin Toh; Celine Prakash; Michelle Hong; Tze Guan Tan; Lin Zheng; Lai Chun Ong; Yi Jin; Masashi Kato; Armelle Prévost-Blondel; Pierce Chow; Henry Yang; Jean-Pierre Abastado
Journal:  J Clin Invest       Date:  2010-05-24       Impact factor: 14.808

Review 2.  Latest developments in the biology and management of uveal melanoma.

Authors:  Sapna P Patel
Journal:  Curr Oncol Rep       Date:  2013-12       Impact factor: 5.075

Review 3.  Dormancy of metastatic melanoma.

Authors:  Liliana Ossowski; Julio A Aguirre-Ghiso
Journal:  Pigment Cell Melanoma Res       Date:  2009-10-19       Impact factor: 4.693

4.  Establishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization.

Authors:  Shinji Ozaki; Raja Vuyyuru; Ken Kageyama; Mizue Terai; Masahiro Ohara; Hanyin Cheng; Tim Manser; Michael J Mastrangelo; Andrew E Aplin; Takami Sato
Journal:  Am J Pathol       Date:  2015-11-25       Impact factor: 4.307

5.  Negative enrichment by immunomagnetic nanobeads for unbiased characterization of circulating tumor cells from peripheral blood of cancer patients.

Authors:  Zhian Liu; Alberto Fusi; Eva Klopocki; Alexander Schmittel; Ingeborg Tinhofer; Anika Nonnenmacher; Ulrich Keilholz
Journal:  J Transl Med       Date:  2011-05-19       Impact factor: 5.531

6.  Tissue-based microarray expression of genes predictive of metastasis in uveal melanoma and differentially expressed in metastatic uveal melanoma.

Authors:  Hakan Demirci; David Reed; Victor M Elner
Journal:  J Ophthalmic Vis Res       Date:  2013-10

7.  Sequential molecular analysis of circulating MCAM/MUC18 expression: a promising disease biomarker related to clinical outcome in melanoma.

Authors:  Maria Cristina Rapanotti; Tara Mayte Suarez Viguria; Gaetana Costanza; Ilaria Ricozzi; Andrea Pierantozzi; Alessandro Di Stefani; Elena Campione; Sergio Bernardini; Sergio Chimenti; Augusto Orlandi; Luca Bianchi
Journal:  Arch Dermatol Res       Date:  2014-06-07       Impact factor: 3.017

Review 8.  Liquid Biopsy in Uveal Melanoma: Are We There Yet?

Authors:  Eva Jin; Julia V Burnier
Journal:  Ocul Oncol Pathol       Date:  2020-07-29

9.  Combination of four gene markers to detect circulating tumor cells in the peripheral blood of patients with advanced lung adenocarcinoma using real-time PCR.

Authors:  Yan Yu; Gang Xu; Jingyan Cao; Shi Jin; Yingchun Man; Lihua Shang
Journal:  Oncol Lett       Date:  2013-02-05       Impact factor: 2.967

10.  Decoding melanoma metastasis.

Authors:  William E Damsky; Lara E Rosenbaum; Marcus Bosenberg
Journal:  Cancers (Basel)       Date:  2010-12-30       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.